RxDoctor Payments Data

Eric Purdy, MD

Ophthalmology · Bluffton, INNPI 1497799472

Payments from drug & device makers

$1,434in general payments, 2019–2025

Across 34 payments — averaging $42.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$431
  • Alcon$356
  • Shire North American Group Inc$132
  • Aerie Pharmaceuticals, Inc.$117
  • Amgen$91
  • Glaukos Corporation$74
  • plus $232 from 6 others

What the payments were for

  • Food & beverage$1,434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,434 in reported general payments places this provider in the 50th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$258,513
Medicare patients
640
Services billed
2,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost132$68,567
RestasisCyclosporine45$44,905
Restasis MultidoseCyclosporine21$13,377
CombiganBrimonidine Tartrate/Timolol29$12,762
RhopressaNetarsudil Mesylate16$10,683
Travoprost53$8,975
SimbrinzaBrinzolamide/Brimonidine Tart12$6,808
Alphagan PBrimonidine Tartrate20$6,080
Prednisolone Acetate141$5,216
Brimonidine Tartrate108$4,780
Cyclosporine16$4,775
Dorzolamide Hcl275$4,503
Latanoprost553$4,186
Brinzolamide31$3,390
Timolol Maleate70$1,759

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Restasis Multidose, Combigan, Alphagan P$431$145,690247 claims
Aerie Pharmaceuticals, Inc.Rhopressa$117$10,68316 claims
AlconSimbrinza$356$6,80812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Bluffton

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →